-- Hubei Jumpcan Pharmaceutical's (SHA:600566) net profit attributable to shareholders in 2025 dropped 30% year on year to 1.78 billion yuan, or 1.93 yuan per share, according to a Shanghai bourse filing on Friday.
Operating revenue fell 22% to 6.22 billion yuan from 8.02 billion yuan in the prior year.